Oxford Biomedica’s (OXB) Buy Rating Reiterated at Jefferies Financial Group

Oxford Biomedica (LON:OXB)‘s stock had its “buy” rating restated by Jefferies Financial Group in a research note issued to investors on Monday, MarketBeat.com reports. They presently have a GBX 827 target price on the biopharmaceutical company’s stock. Jefferies Financial Group‘s target price suggests a potential upside of 56.33% from the stock’s previous close.

Several other research firms have also recently weighed in on OXB. Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of GBX 818.

Oxford Biomedica Trading Up 0.4%

LON OXB opened at GBX 529 on Monday. The firm has a market cap of £640.34 million, a P/E ratio of -16.55 and a beta of 1.11. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. The stock’s 50-day moving average is GBX 495.12 and its 200-day moving average is GBX 612.23. Oxford Biomedica has a one year low of GBX 420 and a one year high of GBX 952.

Oxford Biomedica (LON:OXB) last announced its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. Sell-side analysts anticipate that Oxford Biomedica will post -31.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of Oxford Biomedica stock in a transaction that occurred on Wednesday, September 23rd. The stock was acquired at an average price of GBX 505 per share, for a total transaction of £102,262.50. Insiders own 25.83% of the company’s stock.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.